Population Health Research Institute
Study List

Fondaparinux in ST Elevation Myocardial Infarction. Safety and Efficacy Trial Evaluating Fondaparinux Use in a Broad Range of Patients with ST Segment Elevation Acute MI

  < back


To open a new browser window and visit the OASIS-6 website, please click here.

The purpose of this research study is to determine the efficacy and safety of fondaparinux (Arixtra) in preventing death and repeat heart attacks and their complications in ST-segment elevation acute coronary syndromes.  The trial showed that In patients with STEMI, particularly those not undergoing primary percutaneous coronary intervention, fondaparinux significantly reduces mortality and reinfarction without increasing bleeding and strokes. These findings in conjunction with the results of the OASIS-5 trial led to widespread use of fondaparinux in ACS.

Study Design: Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study.

Intervention: Fondaparinux vs. placebo.

Length of Study: 3 years 

# of Patients: 12,092

Patient Populations: ST-segment elevation acute myocardial infarction.



Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)

Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519-30. Epub 2006 Mar 14







Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca